44-10-208. Feasibility report - standing committee - definition - repeal

44-10-208. Feasibility report - standing committee - definition - repeal. (1) (a) On or before July 1, 2024, the executive director shall submit to the general assembly a report analyzing the feasibility of establishing a standing committee to evaluate cannabinoids and cannabis-derived products for the purpose of determining and making recommendations regarding their safety profiles and potential for intoxication. The report must consider and recommend legislative action addressing the following subjects:

(I) The appropriate state agency or agencies to be involved in, and their role in, the evaluation process;

(II) The ability of a standing committee to determine safety profiles of cannabinoids and cannabis-derived products, including the process by which a standing committee would make such a determination;

(III) The ability of a standing committee to determine the potential for intoxication of cannabinoids and cannabis-derived products, including the process by which a standing committee would make such a determination;

(IV) Recommendations as to members of a standing committee and a process to make appointments of members to a standing committee;

(V) Recommendations regarding an operable timeline for implementation of a standing committee; and

(VI) The fiscal effects of and the resources needed to implement and administer a standing committee.

(b) To inform the feasibility report described in subsection (1)(a) of this section, the department may engage experts, including:

(I) The chief medical officer appointed pursuant to section 25-1-105 or the designee of the chief medical officer;

(II) The state toxicologist or the designee of the state toxicologist;

(III) An epidemiologist with expertise in designing and conducting observational studies or clinical trials;

(IV) A clinician familiar with dosage forms and routes of administration of relevant products;

(V) A medical toxicologist; and

(VI) A pharmacologist with expertise in drug development.

(2) As used in this section, "state toxicologist" means the director of the toxicology and environmental epidemiology office, or a successor office, in the department of public health and environment.

(3) This section is repealed, effective July 1, 2025.